CardioGenics Holdings Inc. - FORM 10-Q - XML - IDEA: XBRL DOCUMENT - June 13, 2012

Attached files
FileFilename
10-Q - FORM 10-Q - CardioGenics Holdings Inc.v315318_10q.htm
XML - IDEA: XBRL DOCUMENT - CardioGenics Holdings Inc.R9.htm
EX-31.1 - EXHIBIT 31.1 - CardioGenics Holdings Inc.v315318_ex31-1.htm
EX-31.2 - EXHIBIT 31.2 - CardioGenics Holdings Inc.v315318_ex31-2.htm
EX-32.1 - EXHIBIT 32.1 - CardioGenics Holdings Inc.v315318_ex32-1.htm
EXCEL - IDEA: XBRL DOCUMENT - CardioGenics Holdings Inc.Financial_Report.xls
XML - IDEA: XBRL DOCUMENT - CardioGenics Holdings Inc.R7.htm
XML - IDEA: XBRL DOCUMENT - CardioGenics Holdings Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - CardioGenics Holdings Inc.R2.htm
XML - IDEA: XBRL DOCUMENT - CardioGenics Holdings Inc.R8.htm
XML - IDEA: XBRL DOCUMENT - CardioGenics Holdings Inc.R5.htm
XML - IDEA: XBRL DOCUMENT - CardioGenics Holdings Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - CardioGenics Holdings Inc.R3.htm
XML - IDEA: XBRL DOCUMENT - CardioGenics Holdings Inc.R17.htm
XML - IDEA: XBRL DOCUMENT - CardioGenics Holdings Inc.R12.htm
XML - IDEA: XBRL DOCUMENT - CardioGenics Holdings Inc.R10.htm
XML - IDEA: XBRL DOCUMENT - CardioGenics Holdings Inc.R15.htm
XML - IDEA: XBRL DOCUMENT - CardioGenics Holdings Inc.R16.htm
XML - IDEA: XBRL DOCUMENT - CardioGenics Holdings Inc.R13.htm
XML - IDEA: XBRL DOCUMENT - CardioGenics Holdings Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - CardioGenics Holdings Inc.R11.htm
v2.4.0.6
Condensed Consolidated Statements of Operations (USD $)
 3 Months Ended 6 Months Ended 173 Months Ended
Apr. 30, 2012
Apr. 30, 2011
Apr. 30, 2012
Apr. 30, 2011
Apr. 30, 2012
Revenue $ 0 $ 0 $ 1,136 $ 0 $ 10,012
Operating Expenses          
Depreciation of Property and Equipment 4,539 4,871 9,094 9,529 210,533
Amortization of Patent Application Costs 1,260 1,090 2,560 2,132 14,971
Write-off of Patent Application Costs 0 0 0 0 214,625
General and Administrative 187,325 383,837 361,488 680,649 7,950,178
Write-off of Goodwill 0 0 0 0 12,780,214
Research and Product Development, Net of Investment Tax Credits 192,694 234,646 348,738 393,570 4,062,496
Cost of Settlement of Lawsuit 0 0 0 0 1,753,800
Total operating expenses 385,818 624,444 721,880 1,085,880 26,986,817
Operating Loss (385,818) (624,444) (720,744) (1,085,880) (26,976,805)
Other Expenses (Income)          
Interest Expense and Bank Charges (Net) 6,014 4,296 9,485 8,900 2,146,121
Loss on Change in Value of Derivative Liability 0 0 0 0 12,421,023
Loss (Gain) on Foreign Exchange Transactions 2,238 91,633 (19,126) 132,163 190,139
Total other expenses (income) 8,252 95,929 (9,641) 141,063 14,757,283
Loss from Continuing Operations (394,070) (720,373) (711,103) (1,226,943) (41,734,088)
Discontinued Operations          
Gain on Sale of Subsidiary 0 0 0 0 90,051
Loss from Discontinued Operations 0 0 0 0 (127,762)
Net Loss (394,070) (720,373) (711,103) (1,226,943) (41,771,799)
Net Loss attributable to non-controlling interest (2,368) (4,688) (4,431) (8,212) (333,955)
Net Loss attributable to CardioGenics Holdings Inc. $ (391,702) $ (715,685) $ (706,672) $ (1,218,731) $ (41,437,844)
Basic and Fully Diluted Net Loss per Common Share attributable to CardioGenics Holdings Inc. Shareholders $ (0.01) $ (0.01) $ (0.01) $ (0.02)  
Weighted-average shares of Common Stock outstanding 55,626,166 54,036,505 55,626,166 53,746,365  

User Contributions:

Comment about this document or add new information about this topic:

CAPTCHA


This web site and associated pages are not associated with, endorsed by, or sponsored by CardioGenics Holdings Inc. and has no official or unofficial affiliation with CardioGenics Holdings Inc.


Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site.  Use at your own risk. This website is not associated with the SEC

Some parts © 2013 Advameg, Inc.